Biologics
& Vaccines
Biologics represent the frontier of medicine — vaccines, monoclonal antibodies, blood products, gene therapies, and cellular therapies. All regulated by FDA's Center for Biologics Evaluation and Research (CBER). This module covers the biologic license application (BLA) pathway, biosimilar approval under BPCIA's 351(k) pathway, the "patent dance" process, vaccine regulation and lot release, blood and tissue regulation, gene and cell therapy oversight, and the Purple Book. With what every regulatory consultant needs to advise biologic clients correctly.
What Is a Biologic — And Why It's Different
Under 42 U.S.C. § 262(i), a biological product is defined as a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product applicable to the prevention, treatment, or cure of a disease or condition. The critical distinction from conventional small-molecule drugs: biologics are derived from living organisms or produced using living cells. They are complex, large-molecule substances that cannot be fully characterized by chemical analysis alone — unlike aspirin (C₉H₈O₄, a fully defined molecule), a monoclonal antibody is a large protein whose exact structure is partially defined by the biological process used to make it.
This complexity is why biologics have their own regulatory framework: they cannot be simply copied the way a small-molecule drug can. A biosimilar is not a generic biologic — it is a product that is "highly similar" to a reference biologic with no clinically meaningful differences in safety, purity, and potency. This distinction has profound regulatory, commercial, and legal implications.
Small-Molecule Drug vs. Biologic — Why They're Regulated Differently
A conventional drug like ibuprofen is a single, fully characterized molecule. Its generic can be chemically identical to the original. A biologic like adalimumab (Humira) is a monoclonal antibody — a large, complex protein made by living cells. Its exact three-dimensional structure depends on the cell line, culture conditions, and purification process. Two manufacturers using the same DNA sequence will produce proteins that are similar but not identical. This is why biosimilars require their own clinical and analytical characterization — you can't just copy the molecule the way you copy aspirin.
What CBER Regulates — The Six Product Categories
CBER has jurisdiction over six broad product categories, each with distinct regulatory requirements. Understanding which CBER office reviews which products is essential before any biologic regulatory engagement.
- Preventive vaccines (influenza, COVID-19, MMR, hepatitis)
- Therapeutic vaccines (cancer vaccines — e.g., Provenge)
- Each lot must pass FDA lot release before distribution
- Potency testing and sterility required for every lot
- Advisory Committee on Immunization Practices (ACIP) makes recommendations after FDA approval
- Whole blood and blood components (RBCs, platelets, FFP)
- Coagulation factors (Factor VIII, IX for hemophilia)
- Plasma-derived products (albumin, IVIG, hyperimmune globulins)
- Blood banks and transfusion services — regulated under 21 CFR Parts 606–640
- Donor screening and testing requirements — HIV, HCV, HBV, syphilis, etc.
- CAR-T cell therapies (Kymriah, Yescarta)
- Gene therapy — viral vector delivery of corrective genes
- Stem cell products
- Tissue-engineered products
- mRNA therapeutics (distinct from mRNA vaccines, which go to OVRR)
- Fastest-growing and most scientifically complex CBER category
- Human cells, tissues, and cellular and tissue-based products (HCT/Ps)
- Corneas, bone, skin, heart valves, tendons
- Reproductive tissues (sperm, eggs, embryos)
- 361 vs. 351 HCT/P distinction determines regulatory pathway
- Donor eligibility, screening, and testing requirements
- Allergenic extracts for diagnosis and immunotherapy
- Patch test kits for contact dermatitis diagnosis
- Licensed under BLA framework
- Potency standardization required for standardized allergens
- Lot release required for some standardized allergens
- Monoclonal antibodies (now regulated by CDER's Office of Biotechnology Products)
- Therapeutic enzymes, cytokines, thrombolytics
- Transferred from CBER to CDER in 2003 — important historical shift
- Most large-molecule biologics that are protein therapeutics are now CDER, not CBER
- BLA pathway regardless of CDER or CBER review
The 2003 Transfer: In 2003, FDA transferred regulatory authority over most therapeutic biological products (including monoclonal antibodies, therapeutic proteins, thrombolytics, cytokines, and growth factors) from CBER to CDER. This is one of the most commonly confused facts in biologics regulation — Humira (adalimumab), Keytruda (pembrolizumab), and Herceptin (trastuzumab) are all regulated by CDER, not CBER, despite being biologics. If you're advising a monoclonal antibody company, their BLA goes to CDER.
The Biologics License Application (BLA)
The primary approval pathway for biologic products is the Biologics License Application, governed by 21 CFR Part 601. The BLA is conceptually similar to an NDA for drugs but has important structural differences reflecting the complexity of biologic manufacturing.
The BLA Manufacturing Section — Why "The Process Is the Product"
The most distinctive feature of biologic regulation is the intimate link between manufacturing process and product characteristics. For a small-molecule drug, you can change suppliers, change synthesis routes, or scale up production with relatively straightforward reporting to FDA. For a biologic, any change to the manufacturing process — cell line, culture media, purification steps, formulation buffers — can alter the product's biological activity, immunogenicity, and safety profile in ways that cannot be fully predicted or detected by end-product testing alone.
This is why the BLA manufacturing section (commonly called the "CMC section" — Chemistry, Manufacturing, and Controls) is enormously detailed for biologics, covering: cell line development and characterization, cell banking system, upstream bioprocessing (fermentation/cell culture), downstream processing (purification), formulation, fill/finish, analytical methods, reference standards, and comparability studies demonstrating that post-approval changes haven't altered the product.
Biosimilars — The 351(k) Pathway
The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created the biosimilar approval pathway — the biologic equivalent of the ANDA for generic drugs. Biosimilar approval is governed by Section 351(k) of the PHS Act. The pathway allows a biosimilar applicant to rely on the FDA's prior determination that the reference biologic is safe and effective — but unlike generic drugs, biosimilars cannot simply copy the innovator's data. They must generate their own extensive analytical and clinical evidence.
Analytical characterization: Extensive side-by-side comparison of structural and functional attributes — primary sequence, higher-order structure, post-translational modifications (glycosylation patterns), binding affinity, Fc function, and other relevant parameters.
Animal studies: Toxicology and PK/PD studies in relevant animal models demonstrating similar behavior.
Human clinical data: Typically a Phase I PK/PD study and a Phase III comparative clinical trial in at least one indication — demonstrating equivalent efficacy and safety with no clinically meaningful differences. Once approved in one indication, extrapolation to other indications the reference product is approved for may be possible without separate clinical trials.
Why this matters: Only interchangeable biosimilars can be automatically substituted by pharmacists without prescriber intervention — just like how a pharmacist can substitute a generic for a brand-name drug. Non-interchangeable biosimilars require a prescriber to specifically prescribe the biosimilar by name. The interchangeability distinction is critical to market access and commercial viability.
First interchangeable: Semglee (insulin glargine-yfgn) was the first FDA-designated interchangeable biosimilar, approved in 2021.
The BPCIA "Patent Dance" — The Most Complex Patent Dispute Process in Law
The BPCIA created a structured, highly specific patent dispute process for biosimilars — nicknamed the "patent dance" because of its elaborate back-and-forth between the biosimilar applicant and the reference product sponsor. Understanding this process is essential for advising biosimilar clients — it determines when a biosimilar can actually enter the market and what patent litigation risks exist.
Vaccine Regulation — The Strictest Product Category
Vaccines are subject to the most rigorous regulatory oversight of any biological product — because they are administered to healthy people, not sick patients. The risk-benefit calculus is fundamentally different: a treatment for cancer might tolerate a higher side-effect profile because the alternative is death. A vaccine given to 300 million healthy people must demonstrate extraordinary safety.
Gene Therapy and Cellular Therapy — The Frontier
Gene therapy and cellular therapy products represent the most rapidly evolving area of FDA regulation. CBER's Office of Cellular Gene and Therapy Products (OCTGT) has approved a growing number of transformative therapies — from CAR-T cell treatments for leukemia to gene therapies correcting inherited blindness.
| Therapy Type | Description | FDA Examples | Key Regulatory Issues |
|---|---|---|---|
| CAR-T Cell Therapy | Patient's T cells extracted, genetically engineered to express chimeric antigen receptor (CAR) targeting cancer cells, then infused back | Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Carvykti | Autologous manufacturing (made from each patient's cells) — unique identity testing challenges; REMS required for cytokine release syndrome monitoring |
| Viral Vector Gene Therapy | Corrective gene delivered into patient cells via viral vector (AAV, lentivirus, retrovirus) | Luxturna (RPE65 retinal dystrophy), Zolgensma (SMA), Hemgenix (hemophilia B) | Long-term safety monitoring required; insertional mutagenesis risk with integrating vectors; manufacturing scale and consistency challenges |
| mRNA Therapeutics | mRNA encoding a therapeutic protein delivered via lipid nanoparticles — patient's cells produce the therapeutic protein | COVID-19 mRNA vaccines (Comirnaty, Spikevax) established the regulatory precedent | Novel platform with emerging regulatory framework; cold chain requirements; immunogenicity of LNP carriers; repeat dosing safety |
| HCT/P — Section 361 vs. 351 | Human cells, tissues, and cellular/tissue-based products — the regulatory pathway depends on manipulation extent and intended use | Section 361 (minimal manipulation, homologous use): bone, corneas, skin — registered under 21 CFR Part 1271. Section 351: more than minimally manipulated or systemic effect — requires BLA. | The 361/351 boundary is frequently litigated; FDA has taken enforcement action against clinics claiming 361 status for manipulated cell products (e.g., stem cell clinics) |
The Stem Cell Clinic Problem: Hundreds of U.S. clinics have marketed unproven stem cell therapies claiming they are "minimally manipulated, homologous use" products under Section 361 of the PHS Act — which would exempt them from BLA requirements. FDA has consistently disagreed, asserting that many of these products are more than minimally manipulated or used for non-homologous purposes, making them unapproved biological drugs. FDA has taken legal action against several clinics and issued warning letters to many others. This is an active enforcement area.
Blood and Blood Products
Blood and blood component regulation under CBER is one of the oldest and most developed areas of biologic regulation. Blood banks, transfusion services, plasma collection centers, and manufacturers of plasma-derived products all fall under CBER's authority.
Biologic Establishment Registration and Licensing
Biologics manufacturers have a dual obligation: establishment registration AND product licensing. Unlike drugs, where facility registration and drug approval are independent, a biologic's license is tied to the specific licensed establishment. If the licensed facility has a serious quality failure, FDA can suspend or revoke the facility's license — which simultaneously removes the license for all products made there.
The Purple Book — Biologics Reference Database
The Purple Book (purplebooksearch.fda.gov) is the biologics equivalent of the Orange Book for drugs. It lists all FDA-licensed biological products, including biosimilars and interchangeable biosimilars. The Purple Book is the starting point for any biosimilar development program — it identifies all approved reference products, their license dates (determining when 12-year exclusivity expires), and the approval status of biosimilars and their interchangeability designations.
| What the Purple Book Shows | Why It Matters for Biosimilar Strategy |
|---|---|
| Reference product name, manufacturer, BLA number | Identifies the exact product a biosimilar applicant must reference in their 351(k) application |
| Date of first licensure | Determines when 12-year reference product exclusivity expires — the earliest date FDA can approve a biosimilar under BPCIA |
| Biosimilar products listed as biosimilar to the reference | Shows the competitive landscape — how many biosimilars are already approved for a given reference product |
| Interchangeability designation | Identifies which biosimilars have been designated interchangeable — critical for pharmacy-level substitution and market access |
| Exclusivity expiry dates | Shows when patent and exclusivity protections expire, informing biosimilar development timing decisions |
South Korean Pharma Company Evaluating a Biosimilar Development Program
A South Korean pharmaceutical company asks Regovant to help them evaluate whether to develop a biosimilar of adalimumab (Humira — reference product from AbbVie). Here is the regulatory orientation you would provide:
- Purple Book check: Adalimumab BLA first licensed in 2002. 12-year exclusivity expired in 2014. There are already 9+ FDA-approved adalimumab biosimilars (Hadlima, Hyrimoz, Cyltezo, Yusimry, Idacio, Hulio, Abrilada, Hadlima SC, Simlandi, etc.). Cyltezo was the first designated interchangeable adalimumab biosimilar (2021).
- Market reality: The U.S. adalimumab biosimilar market is now intensely competitive with multiple interchangeable biosimilars on the market. Pricing competition has been severe — some biosimilars entered at 85%+ discount to Humira's list price.
- Regulatory pathway: 351(k) application to FDA. Must reference adalimumab as the Reference Listed Drug. Need: extensive analytical characterization, animal data, Phase I PK/PD study, and Phase III comparative efficacy trial in at least one approved indication. Total development cost: $100M–$300M. Timeline: 7–10 years from program start to FDA approval.
- Patent dance exposure: AbbVie has an extensive patent portfolio for adalimumab. The patent dance has been extensively litigated for earlier adalimumab biosimilars — the South Korean company should engage patent counsel early to assess Freedom to Operate and litigation exposure before committing capital to the program.
- Regovant's role: Regulatory strategy consulting (identifying the correct regulatory pathway, advising on FDA interactions, reviewing CMC strategy) and potentially pre-BLA meeting preparation. The clinical and patent work requires specialized expertise beyond general FDA regulatory consulting.
- Biologics are regulated under Section 351 of the Public Health Service Act, not the FD&C Act like drugs and devices. The BLA (Biologics License Application) is the primary approval pathway — it licenses both the product AND the manufacturing facility. Changing the manufacturing site requires a Prior Approval Supplement.
- In 2003, FDA transferred most therapeutic protein biologics (monoclonal antibodies, cytokines, growth factors) from CBER to CDER. Most large-molecule biologics are now reviewed by CDER, not CBER. CBER retains jurisdiction over vaccines, blood products, gene and cell therapies, tissues, and allergenics.
- The biosimilar pathway under BPCIA Section 351(k) requires demonstrating "highly similar" to the reference product with "no clinically meaningful differences." Biosimilars are not generics — they require extensive analytical, animal, and clinical data. The 12-year reference product exclusivity is the key exclusivity period (vs. 5 years for NDA drugs).
- Interchangeable biosimilars meet a higher standard than regular biosimilars — they can be automatically substituted by pharmacists without prescriber intervention. Only interchangeable biosimilars have this market access advantage. The Purple Book tracks which biosimilars have interchangeability designations.
- The BPCIA "patent dance" is an elaborate, multi-step patent dispute process that can result in a 30-month automatic stay of biosimilar approval and 180-day notice before commercial marketing. Biosimilar companies must engage patent counsel and strategically navigate this process — regulatory and legal strategy are inseparable in biosimilar development.
- Vaccines require lot release by CBER before distribution — FDA tests every lot for potency, sterility, and safety. This is unique to vaccines. Emergency Use Authorization (EUA) is a separate, faster pathway during public health emergencies that does not confer full FDA approval.
- Gene and cell therapy is the fastest-growing, most scientifically complex area of biologic regulation. CAR-T cell therapies, AAV gene therapies, and mRNA therapeutics all have distinct regulatory considerations. The 361/351 boundary for HCT/Ps is actively litigated — stem cell clinics claiming 361 status for manipulated products are a major ongoing enforcement issue.
Need regulatory strategy for a biologic or biosimilar program?
Regovant provides regulatory orientation, FDA interaction strategy, BLA/351(k) preparation support, and pre-submission meeting preparation for biologic product developers entering the U.S. market.